顺丁烯二酸,替加色罗 以 甲醇,二氯甲烷 用作溶剂,化学反应 1.0H,反应生成马来酸替加色罗 参考文献: Novel Crystalline Forms Of Tegaserod Maleate[fr] Nouvelles Formes Cristallines De Maleate De Tegaserod 标题: Novel Crystalline Forms Of Tegaserod Maleate[fr] Nouvelles Formes Cristallines De Maleate De Tegaserod 摘要:本发明涉及到一种新型的替加色瑞马来酸盐晶体形态,以及制备它们的方法和包含它们的制药组合物.
专利号:US-2009306170-A1 优先权日:2006-11-09 标题:Synthesis of tegaserod or a salt thereof 发明人:GAITONDE ABHAY; MNAOJKUMAR BINDU; SONAWANE SANDEEP 权利人:GENERICS UK LTD 摘要:The present invention relates to a novel process for the synthesis of 1-((5-methoxy-1H-indol-3-yl)methyleneamino)-3-pentyl-guanidine, commonly known as tegaserod, which is used as a gastroprokinetic, and salts thereof. The present invention also relates to tegaserod and salts thereof having an HPLC purity of about 95% or more. The present invention further relates to pharmaceutical compositions comprising tegaserod or a salt thereof, second medical uses of tegaserod or a salt thereof, and methods of treating or preventing irritable bowel syndrome using tegaserod or a salt thereof.
专利号:CN-112921346-A 优先权日:2021-01-25 标题:A kind of electrochemical synthesis method of 3-formyl indole derivatives
专利号:CN-112921346-B 优先权日:2021-01-25 标 题:Electrochemical synthesis method of 3-formyl indole derivative
专利号:CN-101208345-B 优先权日:2005-05-25 标 题 :(S) -N-methylnaltrexone, method of synthesis and pharmaceutical use thereof
1: Pan HC, Shen YQ, Loers G, Jakovcevski I, Schachner M. Tegaserod, a small compound mimetic of polysialic acid, promotes functional recovery after spinal cord injury in mice. Neuroscience. 2014 Sep 26;277:356-66. doi: 10.1016/j.neuroscience.2014.06.069. Epub 2014 Jul 9. doi: 10.1016/j.neuropharm.2013.09.014. Epub 2013 Sep 22. 3: Seeger JD, Quinn S, Earnest DL, Lembo A, Kuo B, Rivero E, Walker AM. The Zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment. BMC Gastroenterol. 2012 Nov 30;12:171. doi: 10.1186/1471-230X-12-171. 4: Wood P. Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits? Naunyn Schmiedebergs Arch Pharmacol. 2012 Jan;385(1):1-3. doi: 10.1007/s00210-011-0694-y. Epub 2011 Oct 4. doi: 10.1007/s00210-011-0687-x. Epub 2011 Sep 8. doi: 10.1097/FPC.0b013e3283469f1d. doi: 10.1111/j.1365-2982.2010.01613.x. Epub 2010 Oct 27.
合成参考文献
参考文献:10.1038/ncb3255 摘要:Lin R, Elf S, Shan C, Kang HB, Ji Q, Zhou L, Hitosugi T, Zhang L, Zhang S, Seo JH, Xie J, Tucker M, Gu TL, Sudderth J, Jiang L, Mitsche M, DeBerardinis RJ, Wu S, Li Y, Mao H, Chen PR, Wang D, Chen GZ, Hurwitz SJ, Lonial S, Arellano ML, Khoury HJ, Khuri FR, Lee BH, Lei Q, Brat DJ, Ye K, Boggon TJ, He C, Kang S, Fan J, Chen J. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat Cell Biol. 2015 Nov;17(11):1484–96.